MedTrace Logo

Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

NCT00238849 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2005-10-14

No results posted yet for this study

Summary

The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.

Conditions

  • Previously Treated Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

Oxaliplatin

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Integrated Community Oncology Network

    lead OTHER

Principal Investigators

  • Thomas A Marsland, MD · Integrated Community Oncology Network

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238849 on ClinicalTrials.gov